Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial (Nature Medicine, (2021), 27, 9, (1536-1543), 10.1038/s41591-021-01444-0)

In the version of this article initially published, there were textual errors in the abstract and main text. In the penultimate sentence of the abstract, the text “immune-related AEs (irAEs) (39.7 versus 18.9%) and grade ≥3 irAEs (7.5 versus 0.7%)” now replaces “immune-related AEs (39.7 versus 18.9%) and grade ≥3 infusion reactions (7.5 versus 0.7%).” In the third paragraph of the “Adverse events” subsection, first sentence, the text “infusion reactions (4.1 versus 4.2%) was similar in the two arms (Supplementary Tables 19–22). In contrast, irAEs as assessed by the investigator” now replaces “infusion reactions (irAEs) (4.1 versus 4.2%) was similar in the two arms (Supplementary Tables 19–22). In contrast, immune-related adverse events.” Further, in Table 2, bottom row “P value” entry, footnote “b” replaces “a”, and in the footnote legend, “a” replaces “*” and “b” replaces “a.” The changes have been made in the online version of the article.